Please login to the form below

Not currently logged in

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Bristol-Myers Squibb (BMS) buildingData shows the combo can improve survival compared to Pfizer’s Sutent

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Sanofi receptionDupixent is still too expensive despite discount, says the UK’s cost effectiveness body

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi receptionCemiplimab could be the first PD-1-targeting drug approved for CSCC

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

First blood to Roche in Hemlibra patent fight with Shire

RocheThe new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

TakedaWill treat perianal fistulas in adult patients with Crohn’s disease

AZ finally gets EU nod for Veltassa rival Lokelma

AstraZeneca AZ headquarters London UKAnd expects a US FDA verdict for the hyperkalaemia treatment later this year

KeysMoving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....